U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents Guidance for Industry August 2013

Final
Docket Number:
FDA-2010-D-0277
Issued by:
Guidance Issuing Office
Center for Tobacco Products

This guidance is intended to assist manufacturers, distributors, retailers, and others who sell cigarettes and/or smokeless tobacco in understanding the final Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents and to explain what you should do in order to comply with the regulations. The document explains, among other things:

  • what and who are subject to the regulations;
  • prohibition on the sale and distribution of certain tobacco products to persons younger than 18 years of age;
  • restrictions on access, which consist largely of requirements concerning the sale of cigarettes and smokeless tobacco; and
  • labeling and advertising restrictions

The regulations currently apply to cigarettes, including roll-your-own tobacco; cigarette tobacco; and smokeless tobacco products (e.g., moist snuff, snus, dry snuff, nasal snuff, loose leaf chewing tobacco, plug chewing tobacco, and twist chewing tobacco).

FDA’s guidances, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2010-D-0277.

Questions?

 
Back to Top